취약 X 증후군(FXS) : 기회 평가와 예측 - 업데이트판

This report covers the US and Germany and provides an Excel-based forecast model for the Fragile X Syndrome market through 2030.

The FXS market in the US and Germany for 2025 is valued at $28.7 million. The market is projected to grow at a compound annual growth rate (CAGR) of 14.7% between 2020 and 2030, reaching $111.9 million by 2030.

The introduction of two pipeline agents is a major driver of growth of the FXS market. In order of entry, these products will be Harmony Biosciences' Zygel and Shionogi's zatolmilast. The sales of high-priced pipeline agents Zygel and zatolmilast represent the most impactful drivers of growth.

Scope

• Overview of Fragile X Sundrome (FXS), including epidemiology, symptoms, diagnosis, and disease management.
• Annualized FXS therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2020 to 2030.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the FXS market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for FXS. The most promising candidates in late-stage development are profiled.
• Analysis of the current and future market competition in the US and German FXS therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the US and German FXS therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the FXS therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents

1. Preface

• 1.1. Contents
• 1.2. Abbreviations
• 1.3. Related Reports

2. Executive Summary

3. Disease Overview

• 3.1. Overview of Fragile X Syndrome
• 3.2. Fragile X Syndrome SWOT Analysis
• 3.3. Progression of Fragile X Syndrome
• 3.4. Diagnosis and Classification of Fragile X Syndrome

4. Epidemiology

• 4.1. Diagnosed Prevalent Cases of FXS, Men and Women, 2020-30
• 4.2. Diagnosed Prevalent Cases of FXS by Sex, 2020
• 4.3. Sources and Methodology: Diagnosed Prevalent Cases of FXS, Men and Women, 2020

5. Current Treatment Options

• 5.1. Treatment Paradigm
• 5.2. Current Treatment Options
• 5.3. Current Treatment Options: KOL Perspective
• 5.4. Product Profile: SSRIs (fluoxetine, sertraline, citalopram, escitalopram)
• 5.5. Product Profile: Other Antidepressants (venlafaxine, bupropion, trazadone)
• 5.6. Product Profile: Psychostimulants (methylphenidate hydrochloride)
• 5.7. Product Profile: Atypical Antipsychotics (aripiprazole, risperidone)
• 5.8. Product Profile: Anticonvulsants (lamotrigine, carbamazepine, sodium valproate)
• 5.9. Product Profile: Antihypertensive Anxiolytics (clonidine, guanfacine)
• 5.10. Product Profile: Benzodiazepines (clonazepam, diazepam)
• 5.11. Product Profile: Lithium (lithium carbonate)
• 5.12. Fragile X Syndrome Cases in 2025 in the US and Germany

6. Unmet Needs and Opportunities

• 6.1. Unmet Needs in Fragile X Syndrome
• 6.2. Therapies that target the underlying etiology of the disease
• 6.3. Improved efficacy and safety profile of behavioral symptomatic treatments
• 6.4. Early diagnosis capability for early intervention

7. R&D Strategies

• 7.1. Trends in Clinical Trial Design in Fragile X Syndrome
• 7.2. Trends in Deal-Making in Fragile X Syndrome

8. Pipeline Assessment

• 8.1. Fragile X Syndrome Pipeline Overview
• 8.2. Late-Stage Pipeline Agents for Fragile X Syndrome
• 8.3. Product Profile: Harmony Biosciences' Zygel (cannabidiol)
• 8.4. Product Profile: Shionogi's zatolmilast
• 8.5. Product Profile: Anavex Life Sciences' blarcamesine hydrochloride
• 8.6. Fragile X Syndrome: Clinical Trials (Phase II/III) Overview

9. Market Outlook

• 9.1. Fragile X Syndrome Market Forecast
• 9.2. Market Drivers and Barriers

10. Appendix

• 10.1. Primary Research: KOL Information
• 10.2. Bibliography
• 10.3. About the Authors

11. Contact Us